Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$2.0 million.

  • Zentalis Pharmaceuticals' Change in Accured Expenses rose 8354.43% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 27813.55%. This contributed to the annual value of -$18.0 million for FY2024, which is 26505.17% down from last year.
  • Latest data reveals that Zentalis Pharmaceuticals reported Change in Accured Expenses of -$2.0 million as of Q3 2025, which was up 8354.43% from -$10.6 million recorded in Q2 2025.
  • In the past 5 years, Zentalis Pharmaceuticals' Change in Accured Expenses ranged from a high of $11.8 million in Q2 2024 and a low of -$15.2 million during Q1 2024
  • Its 4-year average for Change in Accured Expenses is -$543933.3, with a median of -$1.4 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Zentalis Pharmaceuticals' Change in Accured Expenses was 36847.97% (2024), while the steepest drop was 98072.29% (2024).
  • Over the past 4 years, Zentalis Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $5.0 million in 2022, then soared by 105.88% to $10.4 million in 2023, then crashed by 124.64% to -$2.6 million in 2024, then grew by 22.87% to -$2.0 million in 2025.
  • Its Change in Accured Expenses was -$2.0 million in Q3 2025, compared to -$10.6 million in Q2 2025 and -$4.0 million in Q1 2025.